Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

T. Heath, Paul; P. Galiza, Eva; N. Baxter, David; Boffito, Marta; Browne, Duncan; Burns, Fiona; R. Chadwick, David; Clark, Rebecca; Cosgrove, Catherine; Galloway, James; L. Goodman, Anna; Heer, Amardeep; Higham, Andrew; Iyengar, Shalini; Jamal, Arham; Jeanes, Christopher; A. Kalra, Philip; Kyriakidou, Christina; F. McAuley, Daniel; Meyrick, Agnieszka; M. Minassian, Angela; Minton, Jane; Moore, Patrick; Munsoor, Imrozia; Nicholls, Helen; Osanlou, Orod; Packham, Jonathan; H. Pretswell, Carol; San Francisco Ramos, Alberto; Saralaya, Dinesh; P. Sheridan, Ray; Smith, Richard; L. Soiza, Roy; A. Swift, Pauline; C. Thomson, Emma; Turner, Jeremy; E. Viljoen, Marianne; Albert, Gary; Cho, Iksung; Dubovsky, Filip; Glenn, Greg; Rivers, Joy; Robertson, Andreana; Smith, Kathy; Toback, Seth

doi:10.1056/nejmoa2107659

Public

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Published in New England Journal of Medicine • Jun 30, 2021

Authors:

Paul T. Heath

Eva P. Galiza

David N. Baxter

Abstract

BACKGROUND: Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M adjuvant, showed that the ...

Subject

Medicine

Regimen

Intensive care medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!